Abstract: Methods of assessing or evaluating functional properties of T cell therapeutic products are described herein.

Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a modified TGF?RII expression.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.

Abstract: Compositions comprising and methods for the treatment of cancer using a NeoTCR based cell therapy with a secondary Payload in an expression construct.

Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.

Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

Abstract: Methods of detecting the efficacy and presence of a biologic drug which uses one or more 2A peptide in its manufacture and/or final pharmaceutical formulation.

Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

Abstract: The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).

Abstract: Methods of genetically engineering NeoTCR Products comprising young T cells and methods of manufacturing such cell products.

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

Abstract: Methods of treating cancer with a precision genome engineered NeoTCR Product are described herein.

Abstract: Methods of treating cancer in Non-Responder Patients with an engineered NeoTCR Product are described herein.

Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a CD8 expression construct.

Abstract: Compositions comprising and methods for the treatment of cancer using a neoTCR based cell therapy with a knockout of the expression of the TET2 gene.

Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

Abstract: This application relates to use of CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in methods of increasing the number of central memory T cells or for treatment for cancer or for use in cancer vaccine compositions.